1. Home
  2. HURA vs AMPX Comparison

HURA vs AMPX Comparison

Compare HURA & AMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • AMPX
  • Stock Information
  • Founded
  • HURA 2009
  • AMPX 2008
  • Country
  • HURA United States
  • AMPX United States
  • Employees
  • HURA N/A
  • AMPX N/A
  • Industry
  • HURA
  • AMPX Industrial Machinery/Components
  • Sector
  • HURA
  • AMPX Miscellaneous
  • Exchange
  • HURA Nasdaq
  • AMPX Nasdaq
  • Market Cap
  • HURA 246.9M
  • AMPX 206.4M
  • IPO Year
  • HURA N/A
  • AMPX N/A
  • Fundamental
  • Price
  • HURA $4.39
  • AMPX $1.82
  • Analyst Decision
  • HURA
  • AMPX Strong Buy
  • Analyst Count
  • HURA 0
  • AMPX 7
  • Target Price
  • HURA N/A
  • AMPX $8.17
  • AVG Volume (30 Days)
  • HURA 668.3K
  • AMPX 2.8M
  • Earning Date
  • HURA 02-15-2025
  • AMPX 11-07-2024
  • Dividend Yield
  • HURA N/A
  • AMPX N/A
  • EPS Growth
  • HURA N/A
  • AMPX N/A
  • EPS
  • HURA N/A
  • AMPX N/A
  • Revenue
  • HURA N/A
  • AMPX $17,480,000.00
  • Revenue This Year
  • HURA N/A
  • AMPX $132.96
  • Revenue Next Year
  • HURA N/A
  • AMPX $234.85
  • P/E Ratio
  • HURA N/A
  • AMPX N/A
  • Revenue Growth
  • HURA N/A
  • AMPX 196.22
  • 52 Week Low
  • HURA $2.84
  • AMPX $0.61
  • 52 Week High
  • HURA $14.60
  • AMPX $6.02
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • AMPX 45.48
  • Support Level
  • HURA N/A
  • AMPX $1.63
  • Resistance Level
  • HURA N/A
  • AMPX $1.89
  • Average True Range (ATR)
  • HURA 0.00
  • AMPX 0.19
  • MACD
  • HURA 0.00
  • AMPX -0.06
  • Stochastic Oscillator
  • HURA 0.00
  • AMPX 10.78

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About AMPX Amprius Technologies Inc.

Amprius Technologies Inc is engaged in the production of silicon anodes for high energy density lithium-ion batteries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. All of its revenues is geographically earned in the United States.

Share on Social Networks: